EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Accendra Health Inc (ACH) fair value: what the stock is really worth

As of Oct 9, 2026: fair value of Accendra Health Inc $0.49, price $0.43, upside +13.9%, quality 40 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US6907321029

AH Accendra Health Inc logo Thin data Oct 5, 2026

Accendra Health Inc

ACH · US

SpeculativeUpside exists, but weak quality makes the signal speculative.

Fair value $0.4898 · Undervalued (+13.9%)
Quality 40/100
Negative equity (buybacks among others)
Mixed vs. peers (4/9)
Weak Growth (revenue 5y −20.1 %/yr in USD)
Loss-making · -11.4% net margin (TTM)
Negative free cash flow
Narrow moat 10/100 · thin data
Thin data
Watch Accendra Health Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$47.32 $0.4300 Fair Value $0.4898 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 5, 2026.

How to read this chart

60‑month range $0.4300 – $47.32 · fair‑value band $0.2915 – $0.4898 · the $0.4300 price screens below the $0.4898 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 5, 2026.

Follow Accendra Health in your weekly email

Every Wednesday you see whether Accendra Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States.

Show more

Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, including home oxygen and non-invasive ventilation services; obstructive sleep apnea treatment, such as continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services. The company also supplies other home medical equipment, patient care product lines including ostomy, wound care and negative pressure wound therapy, urology, incontinence, and other products and services. It serves patients and home health agencies. The company was formerly known as Owens & Minor, Inc. and changed its name to Accendra Health, Inc. in December 2025. Accendra Health, Inc. was founded in 1882 and is based in Glen Allen, Virginia.

Stock analysis

Accendra Health Inc (ACH) currently trades at $0.4300, while our model-based Fair Value estimate is $0.4898, implying the stock looks roughly 12.2% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 5 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: $0.2915 (bear) to $0.4898 (bull), the price of $0.4300 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Accendra Health Inc reported revenue of $2.8B in FY2025 versus $9.8B in FY2021, a compound −27.1%/yr. Reported net income was −$1.1B in FY2025.

Key figures

Market cap $38.9M · EPS (TTM) $−1.45 · Net margin −39.8% · Return on equity −198% · Return on assets (EBIT) 3.4% · Operating margin −1.5% · Revenue (TTM) $2.6B · Revenue growth (YoY) −10.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades about 92% below its 52-week high and at its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at 37% fair-value upside, at 14%, ACH screens richer than that median.

Fair Value models

Bear $0.2915 Fair Value $0.4898 Bull $0.4898
Price $0.4300 · Upside +13.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV n/a n/a $0.0342 68
ROIC Compounder n/a n/a $0.0899 68
EV/EBITDA $1.09 $1.70 $2.30 66
All 5 models by family
Earnings-Based
EPV n/a n/a $0.0342 68
Multiples
EV/EBIT $0.1878 $0.4898 $0.7915 61
EV/EBITDA $1.09 $1.70 $2.30 66
EV/Revenue n/a $0.2056 $0.4825 50
Economic Profit
ROIC Compounder n/a n/a $0.0899 68

Open the full fair value analysis →

Quality Score breakdown

Overall quality 40/100

Of which business quality 38 · Market factors (momentum, volatility) 3

Profitability 44
Margins and returns on capital today
Quality Growth 40
Are margins and returns improving?
Cashflow 1
Earnings quality: real cash, not paper profit
Fin. Strength 11
Balance sheet, leverage, solvency risk
Investment 90
Disciplined investing over empire-building
Low Volatility 11
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 81
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−74.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−34.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−20.1%
Start year 2020 (pandemic). Over 10 years: −11.9% a year
Revenue growth 40 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
2.4% (2020) → 5.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch ACH, get fair value alerts →

Compare Accendra Health Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 79 stocks

Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 40 · Bottom 25%
Fair Value upside +13.9% · Above median
Profitability
Return on equity (TTM) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets 0.6% · Below median
Net margin (TTM) −11.4% · Bottom 25%
Operating margin (TTM) −1.5% · Bottom 25%
Growth and dividend
Revenue growth −10.1% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM) 0.02× · Cheapest 25%
EV/EBITDA 5.4× · Cheaper than median
PEG 0.70× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)52 · sector 46
FUTURE (revenue growth)0 · sector 14
PAST (return on equity)0 · sector 27
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 58

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Sinopharm Group 1099 HK$14.88 HK$55.77 +275% vs ACH
Shanghai Pharmaceuticals Holding 601607 ¥16.02 ¥42.67 +166% vs ACH
China National Medicines Corporation 600511 ¥25.80 ¥58.47 +127% vs ACH
Jointown Pharmaceutical Group 600998 ¥5.05 ¥9.84 +95% vs ACH
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥19.39 ¥26.64 +37% vs ACH
Henry Schein, Inc HSIC $84.01 $76.77 −9% vs ACH
McKesson Corporation MCK $902.28 $822.74 −9% vs ACH
Galenica AG GALE CHF 82.55 CHF 61.79 −25% vs ACH
Cardinal Health, Inc CAH $228.30 $162.84 −29% vs ACH
Cencora, Inc COR $317.25 $215.20 −32% vs ACH

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Accendra Health Inc · Fair Value
$0.4898 +12%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Accendra Health Inc Fair Value". https://www.fairvalue-calculator.com/stock/ACH

Frequently asked questions

Is Accendra Health Inc (ACH) overvalued or undervalued?
As of Oct 5, 2026, our model estimates a fair value of $0.4898 versus a price of $0.4300, about +14% upside (undervalued).
What is the fair value of ACH?
Our model-based fair value for Accendra Health Inc is $0.4898 (as of Oct 5, 2026), built from audited fundamentals. The current price: $0.4300.
What is the quality score of ACH?
Accendra Health Inc has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Accendra Health Inc (ACH)?
Our model-based price target is the fair value of $0.4898 (as of Oct 5, 2026) from 5 valuation models. Cautious scenario $0.2915, optimistic scenario $0.4898. It is a calculation from audited fundamentals, not an analyst target.
What is the Accendra Health Inc stock forecast for 2026?
Our models put fair value at $0.4898, about +14% upside versus a price of $0.4300 (undervalued). Cautious scenario $0.2915, optimistic scenario $0.4898. The calculation is refreshed regularly with new filings.
What is the revenue of Accendra Health Inc (ACH)?
Accendra Health Inc reported trailing-twelve-month revenue of about $2.6B (latest available figure, as of Oct 5, 2026).
What is the intrinsic value of Accendra Health Inc (ACH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Accendra Health Inc it is $0.4898 per share (as of Oct 5, 2026), against a price of $0.4300. It is the blended result of 5 valuation models (cash flow, earnings, asset, dividend).
Is Accendra Health Inc stock overvalued or undervalued in 2026?
As of Oct 5, 2026, ACH trades below its calculated fair value: price $0.4300, fair value $0.4898, a gap of about +14% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ACH?
No. The price is what the market pays today ($0.4300); the fair value is what the company's own numbers justify ($0.4898). For Accendra Health Inc the two are $0.0598 per share apart. That gap is exactly why we show both numbers side by side.
How much is Accendra Health Inc worth?
The market values Accendra Health Inc at about $38.9M (market capitalisation, as of Oct 5, 2026). Per share that is $0.4300; our models calculate a fair value of $0.4898 per share.
What do the bullish and bearish scenarios say about ACH?
Our models span a range for Accendra Health Inc: cautious scenario $0.2915, base $0.4898, optimistic $0.4898 per share (as of Oct 5, 2026, price $0.4300). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of ACH?
The PEG ratio of Accendra Health Inc is 0.70 (P/E divided by earnings growth, as of Oct 5, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Accendra Health Inc (ACH)?
Balance-sheet figures for Accendra Health Inc (as of Oct 5, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is ACH from its 52-week high?
Accendra Health Inc trades at $0.4300, about 92% below its 52-week high of $5.51 and at the low of $0.4300 (as of Oct 9, 2026). Distance from the high says nothing about value: that is what the fair value of $0.4898 is for.
Which stocks are comparable to Accendra Health Inc?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Accendra Health Inc stock attractive at the current price?
The data as of Oct 5, 2026: price $0.4300, calculated fair value $0.4898 (+14%), Quality Score 40/100, from 5 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ACH calculated?
We run Accendra Health Inc through 5 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.4898, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Accendra Health Inc currently trades 12 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Accendra Health Inc (ACH)?
The closing price on Oct 9, 2026 was $0.4300. Our model-based fair value is $0.4898, about +14% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Accendra Health Inc right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Accendra Health Inc

How large is the market capitalisation of Accendra Health Inc (ACH)?
The market capitalisation of Accendra Health Inc is $38.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Accendra Health Inc (ACH)?
Earnings per share at Accendra Health Inc are $−1.45. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Accendra Health Inc (ACH)?
The net margin of Accendra Health Inc is −39.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Accendra Health Inc (ACH)?
The return on equity (ROE) of Accendra Health Inc is −198% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Accendra Health Inc (ACH)?
On an EBIT basis the return on assets of Accendra Health Inc is 3.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Accendra Health Inc (ACH)?
The operating margin of Accendra Health Inc is −1.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Accendra Health Inc (ACH)?
Revenue at Accendra Health Inc is growing −10.1% versus a year earlier (3y avg −34.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Accendra Health Inc (ACH) generate?
The free cash flow of Accendra Health Inc is −$303M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Accendra Health Inc (ACH) carry?
The net debt of Accendra Health Inc is $2.0B (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Accendra Health Inc in the live analysis

One click puts Accendra Health Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.